| scholarly article | Q13442814 |
| P356 | DOI | 10.1172/JCI18716 |
| 10.1172/JCI200418716 | ||
| P932 | PMC publication ID | 351313 |
| P698 | PubMed publication ID | 14991071 |
| P50 | author | Yasuhiro Ikeda | Q43291521 |
| Thomas Dieterle | Q43892750 | ||
| P2093 | author name string | Kirk L Peterson | |
| Kenneth R Chien | |||
| Yusu Gu | |||
| Masahiko Hoshijima | |||
| Moto-o Date | |||
| Masunori Matsuzaki | |||
| Jacqueline Chrast | |||
| John Ross | |||
| Yoshitaka Iwanaga | |||
| Mitsuo Iwatate | |||
| P2860 | cites work | PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts | Q22254160 |
| The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy | Q24337914 | ||
| Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus | Q24523073 | ||
| Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy | Q24680224 | ||
| Involvement of the cardiac ryanodine receptor/calcium release channel in catecholaminergic polymorphic ventricular tachycardia | Q28216442 | ||
| A calcineurin-dependent transcriptional pathway for cardiac hypertrophy | Q28269300 | ||
| Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure | Q28354203 | ||
| Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy | Q28505358 | ||
| Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. | Q31934499 | ||
| Stress pathways and heart failure | Q33734297 | ||
| Phospholamban and cardiac contractile function | Q33927760 | ||
| In vivo ventricular gene delivery of a beta-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction | Q33936885 | ||
| Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy | Q34048715 | ||
| The nuclear deltaB isoform of Ca2+/calmodulin-dependent protein kinase II regulates atrial natriuretic factor gene expression in ventricular myocytes | Q73919914 | ||
| Frequency-dependent acceleration of relaxation in the heart depends on CaMKII, but not phospholamban | Q74795487 | ||
| Regression of cellular hypertrophy after left ventricular assist device support | Q77142298 | ||
| Hypertrophy and functional alterations in hyperdynamic phospholamban-knockout mouse hearts under chronic aortic stenosis | Q77594865 | ||
| Adrenergic regulation of the force-frequency effect | Q77616661 | ||
| Inotropic therapy for heart failure | Q77685831 | ||
| Molecular mechanisms of myocardial remodeling | Q77918078 | ||
| Upregulated expression of cardiac endothelin-1 participates in myocardial cell growth in Bio14.6 Syrian cardiomyopathic hamsters | Q78108750 | ||
| Targeting phospholamban by gene transfer in human heart failure | Q34074819 | ||
| Decoding calcium signals involved in cardiac growth and function | Q34076156 | ||
| Gene therapy: recombinant adeno-associated virus vectors | Q34119461 | ||
| Cytoplasmic signaling pathways that regulate cardiac hypertrophy | Q34142151 | ||
| Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban | Q34180320 | ||
| Gene therapy: trials and tribulations | Q34186665 | ||
| Dual site phospholamban phosphorylation and its physiological relevance in the heart | Q34536494 | ||
| Mixed signals in heart failure: cancer rules | Q34584027 | ||
| Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human | Q34968216 | ||
| Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure | Q34978011 | ||
| Myocyte death, growth, and regeneration in cardiac hypertrophy and failure | Q35062630 | ||
| Use of echocardiography for the phenotypic assessment of genetically altered mice | Q35127297 | ||
| Adenovirus-based phospholamban antisense expression as a novel approach to improve cardiac contractile dysfunction: comparison of a constitutive viral versus an endothelin-1-responsive cardiac promoter | Q38312488 | ||
| Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms | Q38776803 | ||
| Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy | Q39747918 | ||
| Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene | Q40662320 | ||
| Report of the National Heart, Lung, and Blood Institute Special Emphasis Panel on Heart Failure Research | Q40903719 | ||
| Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration | Q40940810 | ||
| Natural history of left ventricular size and function after acute myocardial infarction. Assessment and prediction by echocardiographic endocardial surface mapping | Q41186747 | ||
| Effects of mutant and antisense RNA of phospholamban on SR Ca(2+)-ATPase activity and cardiac myocyte contractility | Q41687838 | ||
| Progressive cardiac dysfunction and fibrosis in the cardiomyopathic hamster and effects of growth hormone and angiotensin-converting enzyme inhibition | Q41696871 | ||
| Altered membrane proteins and permeability correlate with cardiac dysfunction in cardiomyopathic hamsters | Q41728391 | ||
| Restoration of deficient membrane proteins in the cardiomyopathic hamster by in vivo cardiac gene transfer | Q43869302 | ||
| Myocyte apoptosis: programming ventricular remodeling. | Q44015655 | ||
| Myocardial perfusion-contraction matching. Implications for coronary heart disease and hibernation | Q45051343 | ||
| The left ventricular dP/dtmax-end-diastolic volume relation in closed-chest dogs | Q45297836 | ||
| Efficient and long-term intracardiac gene transfer in delta-sarcoglycan-deficiency hamster by adeno-associated virus-2 vectors | Q45721911 | ||
| Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery | Q45888008 | ||
| Angiotensin II blockade followed by growth hormone as adjunctive therapy after experimental myocardial infarction | Q46110060 | ||
| Endothelial gaps: time course of formation and closure in inflamed venules of rats. | Q50532735 | ||
| Effects of growth hormone on cardiac dysfunction and gene expression in genetic murine dilated cardiomyopathy. | Q52542229 | ||
| The Registry of the International Society for Heart and Lung Transplantation: eighteenth Official Report-2001. | Q53322988 | ||
| Myocardial Infarct Expansion and Matrix Metalloproteinase Inhibition | Q59651627 | ||
| Regulatory Role of Phospholamban in the Efficiency of Cardiac Sarcoplasmic Reticulum Ca2+Transport† | Q62083031 | ||
| Culture and adenoviral infection of adult mouse cardiac myocytes: methods for cellular genetic physiology | Q64380631 | ||
| Adenoviral gene transfer of phospholamban in isolated rat cardiomyocytes. Rescue effects by concomitant gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase | Q64382349 | ||
| Molecular mechanism of regulation of Ca2+ pump ATPase by phospholamban in cardiac sarcoplasmic reticulum. Effects of synthetic phospholamban peptides on Ca2+ pump ATPase | Q68052326 | ||
| Abnormal intracellular calcium handling, a major cause of systolic and diastolic dysfunction in ventricular myocardium from patients with heart failure | Q68447419 | ||
| Advantages and applications of the centerline method for characterizing regional ventricular function | Q69566733 | ||
| Regional remodeling and nonuniform changes in diastolic function in patients with left ventricular dysfunction: modification by long-term enalapril treatment. The SOLVD Investigators | Q72573680 | ||
| Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat | Q72708401 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 727-736 | |
| P577 | publication date | 2004-03-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats | |
| P478 | volume | 113 |
| Q47615347 | A Novel Method for Quantitative Myocardial Contrast Echocardiography in Mice |
| Q45950772 | A Sarcoplasmic Reticulum Localized Protein Phosphatase Regulates Phospholamban Phosphorylation and Promotes Ischemia Reperfusion Injury in the Heart. |
| Q35266526 | A cell-penetrating phospholamban-specific RNA aptamer enhances Ca2+ transients and contractile function in cardiomyocytes |
| Q35132004 | A novel artificial microRNA expressing AAV vector for phospholamban silencing in cardiomyocytes improves Ca2+ uptake into the sarcoplasmic reticulum. |
| Q35238264 | AAV vectors for cardiac gene transfer: experimental tools and clinical opportunities |
| Q44970310 | Adenylyl cyclase type VI corrects cardiac sarcoplasmic reticulum calcium uptake defects in cardiomyopathy |
| Q37766138 | Advances in gene-based therapy for heart failure |
| Q33683757 | Altered intracellular Ca2+ handling in heart failure |
| Q37272838 | An emerging adeno-associated viral vector pipeline for cardiac gene therapy |
| Q37568760 | Antiplatelet therapy attenuates subcellular remodelling in congestive heart failure |
| Q35333572 | Atomic-level mechanisms for phospholamban regulation of the calcium pump. |
| Q44071491 | Augmentation of left ventricular mechanics by recirculation-mediated AAV2/1-SERCA2a gene delivery in experimental heart failure |
| Q37358922 | Beta-adrenergic stimulation and myocardial function in the failing heart |
| Q27026716 | Calcium mishandling in diastolic dysfunction: mechanisms and potential therapies |
| Q34409721 | Cardiac Gene Therapy |
| Q35174923 | Cardiac gene transfer of short hairpin RNA directed against phospholamban effectively knocks down gene expression but causes cellular toxicity in canines |
| Q27691424 | Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure |
| Q27014770 | Cardiovascular gene therapy for myocardial infarction |
| Q33331753 | Cine-MRI versus two-dimensional echocardiography to measure in vivo left ventricular function in rat heart |
| Q36614445 | Creation of a cardiotropic adeno-associated virus: the story of viral directed evolution |
| Q43896155 | Decoy peptides targeted to protein phosphatase 1 inhibit dephosphorylation of phospholamban in cardiomyocytes |
| Q37092093 | Delta-sarcoglycan gene therapy halts progression of cardiac dysfunction, improves respiratory failure, and prolongs life in myopathic hamsters |
| Q37299072 | Designing heart performance by gene transfer. |
| Q40111373 | Differential internalization and nuclear uncoating of self-complementary adeno-associated virus pseudotype vectors as determinants of cardiac cell transduction |
| Q24812916 | Dobutamine stress echocardiography in healthy adult male rats |
| Q90049892 | Downregulation of miR-146a Contributes to Cardiac Dysfunction Induced by the Tyrosine Kinase Inhibitor Sunitinib |
| Q89782554 | Dysregulation of Calcium Handling in Duchenne Muscular Dystrophy-Associated Dilated Cardiomyopathy: Mechanisms and Experimental Therapeutic Strategies |
| Q45865447 | Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo |
| Q46594608 | Enhanced thoracic gene delivery by magnetic nanobead-mediated vector |
| Q37630987 | Factors controlling the activity of the SERCA2a pump in the normal and failing heart. |
| Q39005466 | Functional and physical competition between phospholamban and its mutants provides insight into the molecular mechanism of gene therapy for heart failure. |
| Q48641170 | Gender differences in the expression of genes involved during cardiac development in offspring from dams on high fat diet. |
| Q26863362 | Gene delivery technologies for cardiac applications |
| Q38132253 | Gene therapy for heart disease: molecular targets, vectors and modes of delivery to myocardium |
| Q40014132 | Gene therapy for myocardial infarction-associated congestive heart failure: how far have we got? |
| Q36944623 | Gene therapy in heart failure |
| Q36786243 | Gene therapy in the treatment of heart failure |
| Q27022444 | Gene therapy targets in heart failure: the path to translation |
| Q33605156 | Heart failure management: the present and the future |
| Q28482901 | Heart failure-inducible gene therapy targeting protein phosphatase 1 prevents progressive left ventricular remodeling |
| Q45863016 | Highly efficient and specific modulation of cardiac calcium homeostasis by adenovector-derived short hairpin RNA targeting phospholamban |
| Q80489745 | Increased cardiomyocyte function and Ca2+ transients in mice during early congestive heart failure |
| Q33952558 | Increased infarct wall thickness by a bio-inert material is insufficient to prevent negative left ventricular remodeling after myocardial infarction |
| Q84279517 | Ischemia-reperfusion induces myocardial infarction through mitochondrial Ca²⁺ overload |
| Q53076094 | Left ventricular assist devices: an evolving state of the art. |
| Q38292060 | Lentiviral vector-mediated SERCA2 gene transfer protects against heart failure and left ventricular remodeling after myocardial infarction in rats |
| Q43110528 | Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy |
| Q45185428 | Loss of AKAP150 promotes pathological remodelling and heart failure propensity by disrupting calcium cycling and contractile reserve. |
| Q35621909 | Mechanical stress-strain sensors embedded in cardiac cytoskeleton: Z disk, titin, and associated structures |
| Q54398245 | Metformin improves cardiac function in rats via activation of AMP-activated protein kinase. |
| Q27024714 | MicroRNAs in heart failure: Small molecules with major impact |
| Q26823061 | Model-specific selection of molecular targets for heart failure gene therapy |
| Q35807774 | Models of dilated cardiomyopathy in small animals and novel positive inotropic therapies |
| Q36480080 | Molecular aspects of ischemic heart disease: ischemia/reperfusion-induced genetic changes and potential applications of gene and RNA interference therapy |
| Q40257237 | Mutational screening of phospholamban gene in hypertrophic and idiopathic dilated cardiomyopathy and functional study of the PLN -42 C>G mutation. |
| Q36515530 | New signaling pathways associated with increased cardiac adenylyl cyclase 6 expression: implications for possible congestive heart failure therapy |
| Q51959659 | Noninvasive Doppler-derived myocardial performance index in rats with myocardial infarction: validation and correlation by conductance catheter. |
| Q38966607 | Noninvasive stratification of postinfarction rats based on the degree of cardiac dysfunction using magnetic resonance imaging and echocardiography |
| Q35825873 | Novel therapeutic approaches for heart failure by normalizing calcium cycling |
| Q37941174 | PDE3 inhibition in dilated cardiomyopathy |
| Q45925935 | Partial restoration of left ventricular systolic function by asPLB gene transfer using ultrasound-mediated microbubble destruction. |
| Q54396560 | Percutaneous intracoronary delivery of SERCA gene increases myocardial function: a tissue Doppler imaging echocardiographic study. |
| Q38290254 | Phospholamban Inhibition by a Single Dose of Locked Nucleic Acid Antisense Oligonucleotide Improves Cardiac Contractility in Pressure Overload-Induced Systolic Dysfunction in Mice. |
| Q33639652 | Phospholamban ablation rescues sarcoplasmic reticulum Ca(2+) handling but exacerbates cardiac dysfunction in CaMKIIdelta(C) transgenic mice |
| Q37138913 | Phospholamban overexpression in rabbit ventricular myocytes does not alter sarcoplasmic reticulum Ca transport |
| Q35169578 | Phospholamban phosphorylation, mutation, and structural dynamics: a biophysical approach to understanding and treating cardiomyopathy. |
| Q39356341 | Promise of adeno-associated virus as a gene therapy vector for cardiovascular diseases |
| Q45873132 | Recent findings into the potential of gene therapy to reverse heart failure |
| Q37088473 | Remodeling of calcium handling in human heart failure |
| Q53652278 | Renal denervation mitigates cardiac remodeling and renal damage in Dahl rats: a comparison with β-receptor blockade. |
| Q37644605 | Return of calcium: manipulating intracellular calcium to prevent cardiac pathologies |
| Q37054922 | Role of sarco/endoplasmic reticulum calcium content and calcium ATPase activity in the control of cell growth and proliferation |
| Q41834129 | Sarcolipin and phospholamban inhibit the calcium pump by populating a similar metal ion-free intermediate state. |
| Q38334938 | Small proline-rich protein 1A is a gp130 pathway- and stress-inducible cardioprotective protein |
| Q35763705 | Targeting cardiomyocyte Ca2+ homeostasis in heart failure |
| Q40619242 | Time-resolved FRET reveals the structural mechanism of SERCA-PLB regulation |
| Q37082359 | Toward biologically targeted therapy of calcium cycling defects in heart failure |
| Q47319449 | Transcoronary gene transfer of SERCA2a increases coronary blood flow and decreases cardiomyocyte size in a type 2 diabetic rat model |
| Q35069886 | Update on gene therapy for myocardial ischaemia and left ventricular systolic dysfunction or heart failure |
| Q80218375 | rAAV-mediated angiogenin gene transfer induces angiogenesis and modifies left ventricular remodeling in rats with myocardial infarction |
Search more.